Pfizer's Geodon gets go-ahead for new indication in the US
This article was originally published in Scrip
Executive Summary
The US FDA has expanded the label for Pfizer's Geodon (ziprasidone HCl) to include maintenance treatment of bipolar disorder in adults, as an adjunct therapy to lithium and valproate.